Research Archives - Lewy Body Dementia Association

Join LBDA in Supporting the National Plan to End Parkinson’s

Sometimes it feels like LBD is hidden in the shadows of two more common diseases – Alzheimer’s disease and Parkinson’s disease. But did you know that federal funding of LBD […]

A new biological test may revolutionize diagnosis of Parkinson’s disease and dementia with Lewy bodies

A hallmark brain change associated with both Parkinson’s disease and dementia with Lewy bodies (DLB) is the formation of Lewy bodies in brain cells; Lewy bodies are dense collections of […]

Clinical Trials: New Data and New Opportunities

April 5, 2023 This is an exciting time to follow clinical research in Lewy body dementia. This month we are highlighting updates from recent studies, along with new opportunities to […]

New Clinical Trial: NIA Awards $21M to Study Treatment for DLB

February 8, 2023 Keith Fargo, PhD, Lewy Body Dementia Association Director of Scientific Initiatives The U.S. National Institute on Aging (NIA), part of the National Institutes of Health (NIH), has […]

Clinical Trial of E2027 in DLB Fails

At December’s Clinical Trials in Alzheimer’s Disease conference, Eisai reported that its clinical trial of E2027 in dementia with Lewy bodies (DLB) failed to meet its primary objective. Designed as […]

FDA Approves DaTscan for Dementia with Lewy Bodies

GE Healthcare recently announced the U.S. Food and Drug Administration (FDA) granted marketing approval for its imaging agent, DaTscan, for use in people with suspected dementia with Lewy bodies (DLB). […]

Mouse Model Study Offers Insights on Positive DLB Trial Results

All people with dementia with Lewy bodies (DLB) experience increasing problems with cognition. A very common issue is reduced attention, caused by loss of brain cells that release a chemical […]

Should Medicare pay for the new Alzheimer’s treatment?

When the FDA approved aducanumab for early Alzheimer’s disease, they also required an additional clinical trial to generate more data on its safety and effectiveness. (See LBDA’s earlier position statement […]

NIH funds $35 million study of LBD risk factor

People with rapid eye movement (REM) sleep behavior disorder act out their dreams. While sleeping safely in bed, for example, they might throw up their arms to catch an imaginary […]

LBDA Issues Position Statement on Aducanumab

Key Highlights: The FDA approved marketing of aducanumab for the treatment of Alzheimer’s disease under a special accelerated approval process. Aducanumab has not yet been proven to slow the progression […]

LBDA Research Mentorship Program

The Lewy Body Dementia Association is interested in establishing a Research Mentorship Program. The goal of this program is to promote the continued development of newly trained clinician-researchers, or experienced […]

Statement from LBDA on Hallucination Treatment Rejected by FDA

The Lewy Body Dementia Association is deeply concerned about the recent ruling by the FDA in which it rejected ACADIA Pharmaceutical’s supplemental new drug application for pimavanserin for the treatment […]

LBD Biomarkers: Progress

LBDA’s Research Centers of Excellence (RCOE) program presented a virtual symposium on “biomarkers” on January 25, 2021. A biomarker is a biological sign that reveals the presence or severity of […]

Sitting in the “genetic cross-hairs” of Alzheimer’s and Parkinson’s

Study locates five genes that may play a critical role in Lewy body dementia. Source: National Institutes of Health In a study led by National Institutes of Health researchers, scientists […]

The Virtual Assessment in Lewy Body Dementia: Pandemic and Beyond – A Series of 3 Webinars in 2021

The COVID-19 pandemic necessitated transition of care to telemedicine due to public health concerns. Those with LBD represent a particularly vulnerable population to the complications of COVID-19 given advanced age […]

What’s in a Name? It Depends on Who’s Using It

What’s Alzheimer’s disease (AD)? A person off the street will probably describe a memory problem. A healthcare professional will likely say the same. In fact, AD is what happens at […]

LBDA Partners with Medscape

Despite being a common form of dementia, there is still a tremendous need for more physician education on Lewy body dementia (LBD). To address this issue, LBDA is proud to […]

Shifting into Virtual Mode for LBD Research Meetings

In February of 2020 B.C. (before COVID-19), LBDA planned to host/attend 3 day-long meetings related to LBD research in June in Cleveland, OH. And then the pandemic hit. So, we […]

New Research Definition of Mild Cognitive Impairment with Lewy bodies (MCI-LB)

Most people with Lewy body dementia (LBD) will experience mild changes in thinking; over time, these symptoms, referred to as mild cognitive impairment (MCI), worsen and may become dementia. As […]

Alzheimer’s and Lewy bodies: When Two Pathologies Collide

DLB is one of two clinical diagnoses under the Lewy body dementia umbrella. When DLB co-occurs with Alzheimer’s disease, a clinical diagnosis is even more difficult to make as symptoms […]